机译:用于组合杂化复合纳米片的活性靶向和抗偏移能力的杂化复合纳米型抗逆转能力的官能化策略用于递送5-氟尿嘧啶:朝向结直肠癌治疗
Nanjing Med Univ Affiliated Hosp 1 Dept Gen Surg Nanjing 210029 Peoples R China;
Nanjing Med Univ Affiliated Hosp 1 Colorectal Ctr Dept Gen Surg Nanjing 210029 Peoples R China;
Nanjing Med Univ Affiliated Hosp 1 Dept Gen Surg Nanjing 210029 Peoples R China;
Nanjing Med Univ Affiliated Hosp 1 Dept Gen Surg Nanjing 210029 Peoples R China;
Nanjing Med Univ Affiliated Hosp 1 Dept Gen Surg Nanjing 210029 Peoples R China;
Nanjing Med Univ Affiliated Hosp 1 Dept Gen Surg Nanjing 210029 Peoples R China;
Nanjing Med Univ Affiliated Hosp 1 Dept Gen Surg Nanjing 210029 Peoples R China;
Nanjing Med Univ Affiliated Hosp 1 Colorectal Ctr Dept Gen Surg Nanjing 210029 Peoples R China;
Nanjing Med Univ Affiliated Hosp 1 Dept Gen Surg Nanjing 210029 Peoples R China;
Nanjing Med Univ Affiliated Hosp 1 Dept Gen Surg Nanjing 210029 Peoples R China;
Nanjing Med Univ Sch Pharm Dept Pharmaceut Nanjing 211166 Peoples R China;
Nanjing Med Univ Sch Pharm Dept Pharmaceut Nanjing 211166 Peoples R China;
Nanjing Med Univ Nanjing Hosp 1 Dept Nucl Med Nanjing 210006 Peoples R China;
Nanjing Med Univ Sch Pharm Dept Pharmaceut Nanjing 211166 Peoples R China;
Nanjing Med Univ Affiliated Hosp 1 Colorectal Ctr Dept Gen Surg Nanjing 210029 Peoples R China;
机译:702出版物西妥昔单抗和伊立替康/ 5-氟尿嘧啶(5-FU)/亚叶酸(FA)(AIO)在表达表皮生长因子受体(EGFR)的转移性结直肠癌(mCRC)的一线治疗中是有效且安全的
机译:组合治疗5-氟尿嘧啶和乳酸杆菌治疗癌症癌癌癌释放物的抗癌和抗疟疾效应于结直肠癌细胞上发酵的脱脂乳提取物
机译:用伊立替康/西替昔单抗的治疗序列,然后进行Folfox-4或转移性结肠直肠癌患者的反向策略,在第一线Folfiri / Bevacizumab后进展:用于研究胃肠癌期III的意大利组,随机试验比较两种治疗序列 结肠直肠转移性患者
机译:三联体联合伊立替康(CPT-11)奥沙利铂(LOHP)连续输注5-氟尿嘧啶和亚叶酸(FOLFOXIRI)加西妥昔单抗作为KRAS转移转移性结直肠癌的一线治疗:一项中试II期试验
机译:与Irinotecan(CPT-11),Oxaliplatin(LoHP),连续输注5-氟尿嘧啶和白草(Folfoxiri)加上西妥昔单抗作为克拉斯直肠直肠癌的一线治疗,转移结直肠癌:试验期II试验